Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Saul N Faust

Showing results (181-190 of 225) with videos related to

Pageof 23
Sort By:
Frontiers in Immunology|August 2, 2021
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human TrialHans de Graaf, Ruth O Payne, Iona Taylor, et al.
Nature Communications|January 31, 2024
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Peter W Horby, Leon Peto, et al.
Eclinicalmedicine|January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialKatrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
Science (New York, N.Y.)|April 13, 2013
Ribosomal protein SA haploinsufficiency in humans with isolated congenital aspleniaAlexandre Bolze, Nizar Mahlaoui, Minji Byun, et al.
Lancet (London, England)|August 23, 2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialRobert C Read, David Baxter, David R Chadwick, et al.
Lancet (London, England)|July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
The Journal of Infectious Diseases|October 23, 2014
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individualsSusanne H Hodgson, Katie J Ewer, Carly M Bliss, et al.
The Journal of Infectious Diseases|June 17, 2016
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
Nature Cancer|March 25, 2022
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO studySean H Lim, Beth Stuart, Debora Joseph-Pietras, et al.
Pageof 23

Showing results (181-190 of 225) with videos related to

Sort By:
Pageof 23
Frontiers in Immunology|August 2, 2021
Safety and Immunogenicity of ChAd63/MVA Pfs25-IMX313 in a Phase I First-in-Human TrialHans de Graaf, Ruth O Payne, Iona Taylor, et al.
Nature Communications|January 31, 2024
Dimethyl fumarate in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial, Peter W Horby, Leon Peto, et al.
Eclinicalmedicine|January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialKatrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
Science (New York, N.Y.)|April 13, 2013
Ribosomal protein SA haploinsufficiency in humans with isolated congenital aspleniaAlexandre Bolze, Nizar Mahlaoui, Minji Byun, et al.
Lancet (London, England)|August 23, 2014
Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trialRobert C Read, David Baxter, David R Chadwick, et al.
Lancet (London, England)|July 24, 2020
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M Folegatti, Katie J Ewer, Parvinder K Aley, et al.
The Lancet. Microbe|January 13, 2025
R21 in Matrix-M adjuvant in UK malaria-naive adult men and non-pregnant women aged 18-45 years: an open-label, partially blinded, phase 1-2a controlled human malaria infection studyNavin Venkatraman, Daniel Silman, Duncan Bellamy, et al.
The Journal of Infectious Diseases|October 23, 2014
Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individualsSusanne H Hodgson, Katie J Ewer, Carly M Bliss, et al.
The Journal of Infectious Diseases|June 17, 2016
Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAPTommy Rampling, Katie J Ewer, Georgina Bowyer, et al.
Nature Cancer|March 25, 2022
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO studySean H Lim, Beth Stuart, Debora Joseph-Pietras, et al.
Pageof 23